Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

Literature DB >> 27587385

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

Vikas Gupta¹, Claire Harrison², Elizabeth O Hexner³, Haifa Kathrin Al-Ali⁴, Lynda Foltz⁵, Michael Montgomery⁶, William Sun⁶, Prashanth Gopalakrishna⁷, Hagop Kantarjian⁸, Srdan Verstovsek⁸.

Abstract

Entities: Chemical Disease Species

Keywords: JAK inhibitor; anemia; myelofibrosis; overall survival; ruxolitinib

Mesh：

Substances：
INCB018424
Pyrazoles

Year: 2016 PMID： 27587385 PMCID： PMC5479619 DOI： 10.3324/haematol.2016.151449

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

12 in total

1. MPN-associated myelofibrosis (MPN-MF).

Authors: R A Mesa; A Green; G Barosi; S Verstovsek; J Vardiman; R P Gale
Journal: Leuk Res Date: 2010-08-04 Impact factor: 3.156

2. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

Authors: Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Mario Cazzola; Ayalew Tefferi
Journal: Blood Date: 2010-10-14 Impact factor: 22.113

3. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Authors: Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael W N Deininger; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth O Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; William Sun; Victor Sandor; Hagop M Kantarjian
Journal: Haematologica Date: 2013-09-13 Impact factor: 9.941

4. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Authors: Francisco Cervantes; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Andres Sirulnik; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard S Levy; Francesco Passamonti; Tiziano Barbui; Giovanni Barosi; Claire N Harrison; Laurent Knoops; Heinz Gisslinger
Journal: Blood Date: 2013-10-30 Impact factor: 22.113

5. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Authors: Alessandro M Vannucchi; Hagop M Kantarjian; Jean-Jacques Kiladjian; Jason Gotlib; Francisco Cervantes; Ruben A Mesa; Nicholas J Sarlis; Wei Peng; Victor Sandor; Prashanth Gopalakrishna; Abdel Hmissi; Viktoriya Stalbovskaya; Vikas Gupta; Claire Harrison; Srdan Verstovsek
Journal: Haematologica Date: 2015-06-11 Impact factor: 9.941

6. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors: Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

7. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

8. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.

Authors: Haifa Kathrin Al-Ali; Viktoriya Stalbovskaya; Prashanth Gopalakrishna; Julian Perez-Ronco; Lynda Foltz
Journal: Leuk Lymphoma Date: 2016-02-25

9. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors: Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal: Blood Date: 2008-11-06 Impact factor: 22.113

10. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Authors: Srdan Verstovsek; Jason Gotlib; Vikas Gupta; Ehab Atallah; John Mascarenhas; Alfonso Quintas-Cardama; William Sun; Nicholas J Sarlis; Victor Sandor; Richard S Levy; Hagop M Kantarjian; Ruben A Mesa
Journal: Onco Targets Ther Date: 2013-12-17 Impact factor: 4.147

23 in total

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

1. MPN-associated myelofibrosis (MPN-MF).

2. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

3. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

4. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

5. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

6. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

7. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

8. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.

9. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

10. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Review 1. Management of Myelofibrosis-Related Cytopenias.

Review 2. JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Review 3. New Concepts of Treatment for Patients with Myelofibrosis.

Review 4. SOHO State-of-the-Art Update and Next Questions: MPN.

5. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

6. Disease Modification in Myelofibrosis: An Elusive Goal?

Review 7. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.

Review 8. Ruxolitinib dose management as a key to long-term treatment success.

Review 9. Developmental Therapeutics in Myeloproliferative Neoplasms.

Review 10. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.